Loading the section…
The price of Aurinia Pharmaceuticals Inc (AUPH) on October 9, 2026 is 16.65 USD, +2.65% on the day. Over 52 weeks the stock traded between 10.90 USD and 19.25 USD; the price now sits 69% of the way up that range. Over the past year the price changed by +44.41%. The P/E ratio is 7.3, which is below the sector median (25.0). Market capitalization is 2.18 billion USD, rank 70 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +50.00 %
Aurinia Pharmaceuticals Inc trades on Nasdaq under the ticker AUPH. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks AUPH has traded between 10.90 $ and 19.25 $. As of 9 October 2026 the price stood 68.85 % of the way from the 52-week low to the high.
Over one year AUPH shares rose 44.41 %; over six months they rose 5.65 %. Volatility over 90 days is 38.47 %. Dividends are not included: this is price change only, as of 9 October 2026.
AUPH trades at a price-to-earnings ratio of 7.3, below the sector median of 25.0. Price to sales is 7.3, above the sector median of 4.0. Price to book is 3.8, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 16.16 | 16.97 | 16.12 | 16.65 | 849,200 |
| 8 October 2026 | 15.91 | 16.30 | 15.80 | 16.22 | 831,000 |
| 7 October 2026 | 15.56 | 16.16 | 15.50 | 16.01 | 682,500 |
| 6 October 2026 | 15.77 | 15.82 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Address:#140, 14315 - 118 AVENUE, EDMONTON, AB, T5L 4S6, CA
Aurinia Pharmaceuticals Inc reported revenue of 298M $ and net income of 298M $ over the last four quarters. Net margin is 99.97 %. Revenue changed by +20.62 % year over year. Earnings per share are 2.17 $. Market capitalisation is 2.2B $.
AUPH has a return on equity of 52.54 %, above the sector median of −41.68 %. Return on assets is 41.19 %, above the sector median of −32.11 %. Operating margin is 41.73 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 15.47 |
| 15.69 |
| 698,700 |
| 5 October 2026 | 15.76 | 15.80 | 15.60 | 15.72 | 802,200 |
| 2 October 2026 | 16.06 | 16.06 | 15.74 | 15.83 | 813,400 |
| 1 October 2026 | 16.19 | 16.24 | 15.92 | 15.95 | 933,900 |
| 30 September 2026 | 16.43 | 16.44 | 16.19 | 16.20 | 913,800 |
| 29 September 2026 | 16.39 | 16.48 | 16.16 | 16.42 | 734,700 |
| 28 September 2026 | 16.41 | 16.62 | 16.24 | 16.52 | 626,200 |
| 25 September 2026 | 16.60 | 16.78 | 16.31 | 16.44 | 740,900 |
| 24 September 2026 | 16.35 | 16.66 | 16.28 | 16.60 | 809,200 |
| 23 September 2026 | 16.58 | 16.89 | 16.27 | 16.40 | 787,300 |
| 22 September 2026 | 16.72 | 16.81 | 16.55 | 16.67 | 885,000 |
| 21 September 2026 | 16.90 | 16.92 | 16.56 | 16.61 | 668,300 |
| 18 September 2026 | 16.93 | 17.03 | 16.80 | 16.90 | 1M |
| 17 September 2026 | 17.06 | 17.16 | 16.75 | 16.96 | 850,000 |
| 16 September 2026 | 16.16 | 16.97 | 16.10 | 16.96 | 1M |
| 15 September 2026 | 16.35 | 16.35 | 15.98 | 16.13 | 942,000 |
| 14 September 2026 | 16.03 | 16.52 | 15.93 | 16.41 | 753,500 |